- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Study from NCPA sheds new light on med synchronization programs
- ROUNDTABLE: Pharmacy’s future in sync with technology
EXECUTIVE NEWS — The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO. Neas, currently president and CEO of the National Coalition on Health Care, replaces Kathleen Jaeger, who stepped down as president and CEO of GPhA in May 2010 after eight years with the organization. The GPhA said it planned to spend September introducing Neas to stakeholders in a broad outreach effort.
Neas has worked closely with the generic drug industry over the last three years, promoting generics as a way of saving money while he led the NCHC, and the GPhA will be working with the NCHC’s Cost Containment Alliance.
SUPPLIER NEWS — Par Pharmaceutical will acquire Anchen Pharmaceuticals for $410 million, Par said. Based in Irvine, Calif., Anchen is a privately owned generic drug maker that expects to launch eight to 10 new generic drugs over the next two years.
Hi-Tech Pharmacal has acquired marketing and distribution rights for TussiCaps, available in 10-mg/8-mg and 5-mg/4-mg formulations, from Mallinckrodt. Hi-Tech’s ECR Pharmaceuticals subsidiary, which markets branded prescription products, will promote TussiCaps, the only extended-release prescription cough-cold capsule product approved by the Food and Drug Administration.
In related news, Hi-Tech also recently acquired the marketing and distribution rights to an abbreviated new drug application filing from KVK-Tech for an antihistamine/decongestant product — dexbrompheniramine maleate 6-mg/pseudoephedrine sulfate 120-mg extended-release tablets — which will be marketed by ECR under the brand name Lodrane.
Prasco will market an authorized generic drug for urinary tract infections under an agreement with Shionogi, the company said. Prasco announced that it signed a supply agreement with Shinogi to market and distribute nitrofurantoin oral suspension, an authorized generic version of Furadantin. Last month, the company contracted with Shionogi to sell an authorized generic version of the painkiller Ponstel (mefenamic acid).